PrEP works

iPrEx (Pre-exposure Prophylaxis Initiative) is the first randomised controlled trial of PrEP. The trial proves that taking PrEP provides protection against HIV. In the trial, gay men at high risk of HIV were either given a daily pill containing HIV drugs or a placebo. The HIV infection rate was 44% lower in the group given PrEP. Moreover, for those men who managed to take the pill daily, the infection rate was 73% lower. These results pave the way for PrEP as an HIV prevention method.